Posted by Michael Wonder on 27 May 2021
FDA authorises additional monoclonal antibody for treatment of COVID-19
26 May 2021 - Today, the U.S. FDA issued an emergency use authorisation for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild to moderate COVID-19 in adults and paediatric patients (12 years of age and older weighing at least 40 kg with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalisation or death.
This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions.
